Taladegib

Drug Profile

Taladegib

Alternative Names: LY-2940680

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Ignyta
  • Class Antineoplastics; Benzamides; Fluorobenzenes; Phthalazines; Piperidines; Pyrazoles; Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Oesophageal cancer; Small cell lung cancer
  • Phase I Ovarian cancer; Solid tumours
  • Preclinical Basal cell cancer
  • No development reported Cancer

Most Recent Events

  • 23 Mar 2017 Ignyta amends its license, development and commercialisation agreement with Eli Lilly for taladegib
  • 23 Mar 2017 Taladegib is available for licensing as of 23 Mar 2017. https://ignyta.com/
  • 07 Mar 2017 Phase-I/II clinical trials in Oesophageal cancer (Combination therapy) in USA (PO) (NCT02530437)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top